Pipeline

BP1.15205, an investigational compound, is a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for treatment of symptoms of narcolepsy and other sleep/wake disorders. BP1.15205 represents a new chemical series of OX2R agonists.

CBS-105 is an investigational novel regenerative cellular therapy being developed with the aim to replace lost neurons and restore their function in patients with treatment-resistant narcolepsy.

HBS-102, an investigational compound, is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. Melanin-concentrating hormone neurons are located in the hypothalamus and are involved in several different functions, including feeding behaviors, energy balance and control of metabolic functions, rapid eye movement (REM) sleep, and mood and behavioral processing, among others.

ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). ZYN002 is the first-and-only pharmaceutically manufactured synthetic cannabidiol devoid of THC and formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. The product is manufactured through a synthetic process in a cGMP facility and is not extracted from the cannabis plant. ZYN002 does not contain THC, the compound that causes the euphoric effect of cannabis.

Cannabidiol, the active ingredient in ZYN002, has been granted orphan drug designation by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of FXS and for the treatment of 22q. Additionally, ZYN002 has received FDA fast track designation for the treatment of behavioral symptoms in patients with FXS.

EPX-100, an investigational compound, modulates serotonin signaling by targeting central 5-hydroxytryptamine (5-HT) receptor subtypes. EPX-100 has been granted orphan drug designation by the United States Food and Drug Administration (FDA) for the treatment of Dravet syndrome (DS) and for the treatment of Lennox-Gastaut syndrome (LGS). Additionally, EPX-100 has received FDA rare pediatric disease designation for the treatment of DS and for the treatment of LGS.

EPX-200 is a potent, oral, centrally active and selective 5HT2C agonist and is currently in IND-enabling studies. EPX-200 is a liquid formulation of lorcaserin.

CBS-104 is an investigational novel regenerative cellular therapy being developed with the aim to replace lost neurons and restore their function in patients with refractory epilepsy.